Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 2343

1.

Association between triglyceride levels and cardiovascular disease in patients with acute pancreatitis.

Copeland LA, Swendsen CS, Sears DM, MacCarthy AA, McNeal CJ.

PLoS One. 2018 Jan 30;13(1):e0179998. doi: 10.1371/journal.pone.0179998. eCollection 2018.

2.

Dyslipidemia, chronic inflammation, and subclinical atherosclerosis in children and adolescents infected with HIV: The PositHIVe Health Study.

Augustemak de Lima LR, Petroski EL, Moreno YMF, Silva DAS, Trindade EBMS, Carvalho AP, Back IC.

PLoS One. 2018 Jan 10;13(1):e0190785. doi: 10.1371/journal.pone.0190785. eCollection 2018.

3.

Elevated serum lipoprotein(a) as a risk factor for combined intracranial and extracranial artery stenosis in a child with arterial ischemic stroke: A case report.

Han JY, Kim HJ, Shin S, Park J, Lee IG.

Medicine (Baltimore). 2017 Dec;96(49):e9025. doi: 10.1097/MD.0000000000009025.

4.

The nutraceutical benefits of subfractions of Abelmoschus esculentus in treating type 2 diabetes mellitus.

Huang CN, Wang CJ, Lin CL, Lin HT, Peng CH.

PLoS One. 2017 Dec 7;12(12):e0189065. doi: 10.1371/journal.pone.0189065. eCollection 2017.

5.

Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.

Agrawal S, Zaritsky JJ, Fornoni A, Smoyer WE.

Nat Rev Nephrol. 2018 Jan;14(1):57-70. doi: 10.1038/nrneph.2017.155. Epub 2017 Nov 27. Review. Erratum in: Nat Rev Nephrol. 2017 Dec 13;14 (1):70.

6.

An electronic health record based model predicts statin adherence, LDL cholesterol, and cardiovascular disease in the United States Military Health System.

Lucas JE, Bazemore TC, Alo C, Monahan PB, Voora D.

PLoS One. 2017 Nov 20;12(11):e0187809. doi: 10.1371/journal.pone.0187809. eCollection 2017.

7.

LDL-cholesterol goal attainment under persistent lipid-lowering therapy in northeast China: Subgroup analysis of the dyslipidemia international study of China (DYSIS-China).

Zheng W, Zhang YJ, Bu XT, Guo XZ, Hu DY, Li ZQ, Sun J.

Medicine (Baltimore). 2017 Nov;96(46):e8555. doi: 10.1097/MD.0000000000008555.

8.

Everolimus for pediatric patients with acute graft-versus-host disease after hematopoietic stem cell transplantation: A pilot study.

Chao YH, Chang YC, Wu HP, Peng CT, Weng TF, Wu KH.

Medicine (Baltimore). 2017 Nov;96(44):e8464. doi: 10.1097/MD.0000000000008464.

9.

Familial hypercholesterolemia in Chinese patients with premature ST-segment-elevation myocardial infarction: Prevalence, lipid management and 1-year follow-up.

Auckle R, Su B, Li H, Xu S, Xie M, Song Y, Abdul Quddus M, Xu Y, Liu B, Che W.

PLoS One. 2017 Oct 31;12(10):e0186815. doi: 10.1371/journal.pone.0186815. eCollection 2017.

10.

The correlation between serum free thyroxine and regression of dyslipidemia in adult males: A 4.5-year prospective study.

Wang H, Liu A, Zhou Y, Xiao Y, Yan Y, Zhao T, Gong X, Pang T, Fan C, Zhao J, Teng W, Shan Z, Lai Y.

Medicine (Baltimore). 2017 Sep;96(39):e8163. doi: 10.1097/MD.0000000000008163.

11.

Xuezhikang contributes to greater triglyceride reduction than simvastatin in hypertriglyceridemia rats by up-regulating apolipoprotein A5 via the PPARα signaling pathway.

Zhao SP, Li R, Dai W, Yu BL, Chen LZ, Huang XS.

PLoS One. 2017 Sep 21;12(9):e0184949. doi: 10.1371/journal.pone.0184949. eCollection 2017.

12.

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives.

Catapano AL, Pirillo A, Norata GD.

Vasc Health Risk Manag. 2017 Sep 4;13:343-351. doi: 10.2147/VHRM.S130338. eCollection 2017. Review.

13.

Predicted impact of lipid lowering therapy on cardiovascular and economic outcomes of Swedish atherosclerotic cardiovascular disease guideline.

Journath G, Hambraeus K, Hagström E, Pettersson B, Löthgren M.

BMC Cardiovasc Disord. 2017 Aug 16;17(1):224. doi: 10.1186/s12872-017-0659-2.

14.

Antihyperlipidaemic and hepatoprotective activities of acidic and enzymatic hydrolysis exopolysaccharides from Pleurotus eryngii SI-04.

Zhang C, Li J, Wang J, Song X, Zhang J, Wu S, Hu C, Gong Z, Jia L.

BMC Complement Altern Med. 2017 Aug 14;17(1):403. doi: 10.1186/s12906-017-1892-z.

15.

Cardiovascular risk and dyslipidemia among persons living with HIV: a review.

Maggi P, Di Biagio A, Rusconi S, Cicalini S, D'Abbraccio M, d'Ettorre G, Martinelli C, Nunnari G, Sighinolfi L, Spagnuolo V, Squillace N.

BMC Infect Dis. 2017 Aug 9;17(1):551. doi: 10.1186/s12879-017-2626-z. Review.

16.

Green tea polyphenol treatment attenuates atherosclerosis in high-fat diet-fed apolipoprotein E-knockout mice via alleviating dyslipidemia and up-regulating autophagy.

Ding S, Jiang J, Yu P, Zhang G, Zhang G, Liu X.

PLoS One. 2017 Aug 4;12(8):e0181666. doi: 10.1371/journal.pone.0181666. eCollection 2017.

17.

Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.

Jetty V, Glueck CJ, Lee K, Goldenberg N, Prince M, Kumar A, Goldenberg M, Anand I, Wang P.

Vasc Health Risk Manag. 2017 Jul 6;13:247-253. doi: 10.2147/VHRM.S133690. eCollection 2017.

18.

CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects.

Thomas T, Zhou H, Karmally W, Ramakrishnan R, Holleran S, Liu Y, Jumes P, Wagner JA, Hubbard B, Previs SF, Roddy T, Johnson-Levonas AO, Gutstein DE, Marcovina SM, Rader DJ, Ginsberg HN, Millar JS, Reyes-Soffer G.

Arterioscler Thromb Vasc Biol. 2017 Sep;37(9):1770-1775. doi: 10.1161/ATVBAHA.117.309549. Epub 2017 Jul 20.

19.

The prevalence of familial hypercholesterolemia in the West Siberian region of the Russian Federation: A substudy of the ESSE-RF.

Ershova AI, Meshkov AN, Bazhan SS, Storozhok MA, Efanov AY, Medvedeva IV, Indukaeva EV, Danilchenko YV, Kuzmina OK, Barbarash OL, Deev AD, Shalnova SA, Boytsov SA.

PLoS One. 2017 Jul 18;12(7):e0181148. doi: 10.1371/journal.pone.0181148. eCollection 2017.

20.

Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia.

Boccara F, Dent R, Ruilope L, Valensi P.

Adv Ther. 2017 Aug;34(8):1876-1896. doi: 10.1007/s12325-017-0586-8. Epub 2017 Jul 17. Review.

Supplemental Content

Loading ...
Support Center